Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2017-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Acquired epidermal growth factor receptor (EGFR) T790M mutation is the most common genetic change after resistant to first generation EGFR tyrosine kinase inhibitor (EGFR TKI) in non-small cell lung cancer. After a 10 to 14 months median progression-free survival with the treatment of first generation EGFR TKI, half of patients will get disease progression.For patients progression after treated with first line EGFR TKI and second line double bullets chemotherapy or chemotherapy then EGFR TKI, optimal third line therapy is quite critical important for benefit patients' survival. We conducted this study was aimed to compare the efficacy and toxicity between osimertinib and docetaxel-bevacizumab as the third line therapy in patients with local advanced or metastatic non-squamous cell lung cancer.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qingdao Central Hospital
• Treatments: Bevacizumab; Docetaxel; Osimertinib

Criteria

Inclusion Criteria:

• local advanced or metastatic non-small cell lung cancer

• large cell lung carcinoma or adenocinoma

• Previously treated by TKI-Chemotherapy or Chemotherapy-TKI

• EGFR T790M positive

• No uncontrolled hypertension

• No active bleeding or thrombosis in recent 6 months

• No previously treated with VEGF antibody

Exclusion Criteria:

• newly diagnosed thrombosis

• anti-coagulation therapy

• uncontrolled hypertension

• uncontrolled nephropathy